Nevertheless, further studies were validated not only because there were indications that a subset of patients with moderately severe COPD might have benefitted by oxygen supplementation but also ...

Please provide your email address to receive an email when new articles are posted on . Patients with moderate or severe COPD experienced improvements with 3 mg of twice-daily ensifentrine. Study ...

Patients were recruited by their family physician from 7 primary care practices in Palma de Mallorca, Spain, from July 2005 to March 2007. Patients were identified from both the health center COPD ...

Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a history of ...

Please provide your email address to receive an email when new articles are posted on . Risk estimation was based on area under the receiver operating characteristic curve, sensitivity and specificity ...

BARCELONA -- The need for antibiotics in patients with chronic obstructive pulmonary disease (COPD) seeking treatment for moderate acute COPD exacerbations could not be ruled out in a randomized trial ...

GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.

The clinical and survival benefit of home oxygen therapy, both LTOT and nocturnal oxygen therapy, for patients with COPD and moderate hypoxemia was evaluated in this meta-analysis. Home oxygen therapy ...

Results from 2 COPD phase 3 trials suggest that targeting the IL-33 pathway with tozorakimab delivers meaningful clinical benefit.

Certain glucose-lowering drugs were linked to fewer moderate or severe COPD exacerbations in adults with type 2 diabetes Study: Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary ...

Positive high‑level results from the phase 3 OBERON and TITANIA trials indicate that tozorakimab achieved statistically significant and clinically meaningful reductions in the a ...

AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically ...